TrialClinical pharmacology in drug development2021

Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.

Donna S Cox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.